Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

AYVAKIT's multibillion-dollar potential and BLU-808 breakthroughs drive BPMC's meteoric rise in biotech innovation.

Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritin ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on BPMC stock, giving a Hold rating on January 9.Stay Ahead of the ...

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin. Maurer was an author ...

Investing.com -- Shares of Blueprint Medicines (NASDAQ: BPMC) Corporation (NASDAQ:BPMC) climbed 17% as the company outlined its growth strategy for 2025, highlighting the potential of its systemic ...

A recent study published in Science Translational Medicine has examined a new approach to address inflammatory skin diseases, such as dermatitis and rosacea, by focusing on a specific glutamate ...

aiming to develop a flexible treatment approach and optimize the benefit-risk profile for a range of mast cell-driven ...

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Talia Lavin, 42, from Massachusetts, US, was prescribed the antibiotic Ciprofloxacin for a urinary tract infection - but the ...